Share this post:

Josefien will present the key findings of the first-ever AMR Benchmark, which shows how large research-based pharmaceutucal companies, generic medicine manufacturers and biopharmaceutical firms are addressing AMR and where further action is needed. Currently, the Access to Medicine Foundation research team is working on the metrics for the next AMR Benchmark that will be published in 2020.

Related posts